Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 20, 2015
The Diversity of Biosimilar Design and Development: Implications for Policies and StakeholdersGustavo Grampp, Sundar RamananExpert Review of Clinical Pharmacology|January 7, 2014
Preventing shortages of biologic medicinesSundar Ramanan, Gustavo GramppBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Drift, evolution, and divergence in biologics and biosimilars manufacturingSundar Ramanan, Gustavo GramppBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 27, 2013
Managing unexpected events in the manufacturing of biologic medicinesGustavo Grampp, Sundar RamananNephrology News & Issues|December 19, 2015
Study design is important for ESA biosimilarsAllan Pollock, Gustavo GramppBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2015
Pharmacovigilance Considerations for Biosimilars in the USAGustavo Grampp, Thomas FelixJournal of Managed Care & Specialty Pharmacy|June 26, 2015
Pharmacist Substitution of Biological Products: Issues and ConsiderationsEdward Li, Sundar Ramanan, Larry GreenCurrent Medical Research and Opinion|April 24, 2012
Comparability and biosimilarity: considerations for the healthcare providerJaymi F Lee, Jason B Litten, Gustavo GramppMabs|April 23, 2011
Biosimilars 2.0: guiding principles for a global "patients first" standardJoseph Miletich, Geoffrey Eich, Gustavo Grampp, et al.Biologicals : Journal of the International Association of Biological Standardization|November 1, 2019
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case studyRobin Thorpe, Gustavo Grampp, Hye-Na Kang, et al.Pageof 2